July 7, 2017 / 1:38 PM / 3 months ago

BRIEF-Lexicon Pharmaceuticals amends collaboration and license agreement

July 7 (Reuters) - Lexicon Pharmaceuticals Inc:

* Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH

* Lexicon Pharmaceuticals Inc - remain eligible to receive an aggregate of $210 million upon achievement of amended clinical development milestones

* Lexicon Pharmaceuticals - remain eligible to receive up to $220 million upon achievement of specified regulatory milestones

* Lexicon Pharmaceuticals - remain eligible to receive up to $990 million upon the achievement of specified commercial milestones

* Lexicon Pharmaceuticals - under amended milestones, eligible to receive up to $110 million upon achievement of 4 milestones

* Lexicon Pharma-pursuant to amendment, co eligible to $100 million upon achievement of milestone based on results of studies in type 2 diabetes patients Source text - bit.ly/2uRPbnA Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below